ReviewFrontiers in immunology2026
The emerging role of histone acetylation in rheumatic diseases: unraveling mechanisms and therapeutic prospects.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Histone modifications in skin fibrosis: linking immune dysregulation, metabolic reprogramming, and persistent fibrotic remodeling.Frontiers in immunology · 2026Review
- Metabolic-epigenetic rewiring in rheumatoid arthritis: from pathogenic memory to precision restoration.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histone acetylation, a fundamental and reversible epigenetic modification, critically regulates chromatin structure and plays a pivotal role in diverse cellular processes, including gene transcription, cell cycle progression, and DNA damage repair. Rheumatic diseases [such as rheumatoid arthritis (RA), osteoarthritis (OA), and systemic lupus erythematosus (SLE)] represent a group of disorders primarily affecting joints, bones, muscles, and connective tissues, posing a significant global burden. This review systematically elucidated the aberrant regulation of histone acetylation in these rheumatic conditions, with a focus on the disrupted balance between histone acetyltransferases (HATs) and histone deacetylases (HDACs). We further discussed the downstream mechanisms driven by these acetylation alterations, which contribute to various pathological processes (including synovial inflammation, cartilage degradation, and dysregulated cell death). Notably, special emphasis is placed on the potential of traditional Chinese medicine (TCM) to target this epigenetic axis. We summarized evidence that TCM formulations can exert their therapeutic effects by modulating HAT/HDAC activity and restoring acetylation homeostasis. By integrating current knowledge, this review aimed to provide mechanistic insights and highlight the promising potential of targeting histone acetylation, especially through TCM-based strategies, for developing novel therapeutic strategies against rheumatic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.